Clinical Trials Logo

Clinical Trial Summary

This is a randomized controlled clinical trial comparing treatment success of a gene-derived individualized drug-resistant Tuberculosis regimen to a standard Tuberculosis regimen based on South African National Tuberculosis guidelines.

Clinical Trial Description

When drug resistance is detected by molecular methods such as the Xpert MTB/RIF assay, second-line Multi Drug-Resistant (MDR) Tuberculosis treatment is started in the complete absence of detailed resistance information. The diagnosis of Multi Drug-Resistant Tuberculosis is confirmed only on availability of Line Probe Assay (LPA)/Drug Susceptibility Testing (DST) results. Extremely Drug-Resistant (XDR) Tuberculosis is diagnosed by in vitro phenotypic resistance to Rifampicin, Isoniazid, fluoroquinolones and injectable second-line drugs (i.e., amikacin, kanamycin, or capreomycin). Existing culture based Drug Susceptibility Testing provides results after 6-8 weeks. This duration may be further increased by other existing laboratory challenges, such as culture contamination.

Furthermore, initial regimens are often not optimal and sometimes completely ineffective as there is a lack of Drug Susceptibility Testing to support them. More importantly, even optimal regimens are changed due to patient intolerance of the drug's side effects.

Whole Genome Sequencing (WGS) has the advantage of determining the complete Deoxyribonucleic acid (DNA) sequence of an organism's genome at a single time point. Using this technology, genotypic mutations conferring resistance to anti-tuberculosis drugs can be identified. This information will assist in identifying not only potential resistant drugs, but also susceptible drugs and thus enable a more accurate and appropriate choice of regimen. In addition, drugs that will not add value to the treatment outcome, but will increase rates of adverse drug reactions, can be eliminated earlier, improving drug-resistant TB treatment outcomes.

In this proposal, we aim to use Mycobacterium Tuberculosis (MTB) whole genome sequencing prior to the selection of a drug-resistant tuberculosis treatment regimen and thus provide an individualized treatment strategy for drug-resistant tuberculosis. By adopting this method, we hope to improve culture negative survival rates at 6 months post treatment initiation .

This study will include 448 adult patients (age ≥ 18 years) that meet inclusion criteria. Patients referred by provincial satellite facilities with microbiological confirmation of drug-resistant tuberculosis (e.g. Xpert MTB/RIF assay / Line Probe Assay) to King DinuZulu Hospital (KDH) will be recruited. Patients randomized to the control arm will receive standard of care (SOC) treatment. Patients randomized to the intervention arm will be given an individualized treatment regimen based on whole genome sequencing conducted on Mycobacteria Growth Indicator Tube (MGIT) positive sputum samples collected at the screening visit. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT03237182
Study type Interventional
Source Centre for the AIDS Programme of Research in South Africa
Contact Natasha Gounden, BMedSc
Phone 0832283363
Status Recruiting
Phase Phase 4
Start date June 14, 2017
Completion date December 2021

See also
  Status Clinical Trial Phase
Recruiting NCT02715271 - Study of TB Lesions Obtained in Therapeutical Surgery
Recruiting NCT03086486 - Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary TB, XDR-TB, Pre- XDR-TB or Non-responsive/Intolerant MDR-TB (ZeNix) Phase 3
Completed NCT01201941 - Operational Assessment of Laboratory Information System for MDR-TB in Lima, Peru N/A
Recruiting NCT03303963 - DIAgnostics for Multidrug Resistant Tuberculosis in Africa N/A
Recruiting NCT02413931 - Nosocomial Transmission of MDR-TB in Bucharest, Romania
Recruiting NCT02597621 - Biomarkers for Therapy Response in Drug-resistant Tuberculosis N/A
Completed NCT02573350 - A Phase 2, Multi-center, Uncontrolled, Open-label Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683 Phase 2
Recruiting NCT03338621 - Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients Phase 2
Recruiting NCT02589782 - Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s) Phase 2/Phase 3
Recruiting NCT02619994 - Treatment Shortening of MDR-TB Using Existing and New Drugs Phase 2
Active, not recruiting NCT01918397 - Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB Phase 2
Completed NCT00513396 - High-Dose Isoniazid Adjuvant Therapy for Multidrug Resistant Tuberculosis Phase 2/Phase 3
Recruiting NCT03259269 - Expand New Drugs for TB [endTB]
Completed NCT01071603 - Tuberculosis in China
Active, not recruiting NCT02365623 - An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB) Phase 2
Recruiting NCT03409315 - Feasibility of Centralized Therapeutic Drug Monitoring of Fluoroquinolones in Multi-Drug Resistant Tuberculosis Patients
Recruiting NCT02754765 - Evaluating Newly Approved Drugs for Multidrug-resistant TB Phase 3
Not yet recruiting NCT03728725 - Xpert MTB/XDR Clinical Evaluation Trial
Completed NCT02170441 - Global Consortium for Drug-resistant Tuberculosis Diagnostics N/A